New cellular and molecular mechanisms of lung injury and fi brosis in idiopathic pulmonary fi brosis

The Lancet

Volumn 380, Issue 9842, 2012, Pages 680-688

  Fernandez, Isis E ^a,b   Eickelberg, Oliver ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BLEOMYCIN; CALVASCULIN; FIBRONECTIN; ILOPROST; LET 7D; LYSOPHOSPHATIDIC ACID; LYSYL OXIDASE LIKE 2; MICRORNA; MICRORNA 200; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AB0023; OXIDOREDUCTASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PREDNISONE; PROSTAGLANDIN E2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SMAD PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

ALLOSTERISM; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL ACTIVATION; CELL MEMBRANE; CLINICAL FEATURE; CLINICAL RESEARCH; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS CELL; LUNG BIOPSY; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG FUNCTION; LUNG INJURY; MEDIATOR; MESOTHELIUM CELL; MORTALITY; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERICYTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECEPTOR DOWN REGULATION; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 84865113809     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61144-1     Document Type: Review

References (96)

1. Eickelberg O, Selman M. Update in diff use parenchymal lung disease 2009. Am J Respir Crit Care Med 2010; 181: 883-88.
2. Raghu G, Collard HR, Egan JJ, et al. An offi cial ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fi brosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
3. Oh CK, Murray LA, Molfi no NA. Smoking and idiopathic pulmonary fi brosis. Pulm Med 2012; 2012: 808260.
4. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal refl ux in idiopathic pulmonary fi brosis. Eur Respir J 2006; 27: 136-42.
5. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal refl ux therapy is associated with longer survival in patients with idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2011; 184: 1390-94.
6. Taskar VS, Coultas DB. Is idiopathic pulmonary fi brosis an environmental disease? Proc Am Thorac Soc 2006; 3: 293-98.
7. Lasithiotaki I, Antoniou KM, Vlahava VM, et al. Detection of herpes simplex virus type-1 in patients with fi brotic lung diseases. PLoS One 2011; 6: e27800.
8. Faner R, Rojas M, Macnee W, Agusti A. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2012; published online May 10. DOI:10.1164/rccm.201202-0282PP.
9. Wynn TA. Integrating mechanisms of pulmonary fi brosis. J Exp Med 2011; 208: 1339-50.
10. Konigshoff M, Eickelberg O. WNT signaling in lung disease: a failure or a regeneration signal? Am J Respir Cell Mol Biol 2010; 42: 21-31.
11. Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 2010; 298: L715-31.
12. Aoyagi-Ikeda K, Maeno T, Matsui H, et al. Notch induces myofi broblast diff erentiation of alveolar epithelial cells via transforming growth factor-?-Smad3 pathway. Am J Respir Cell Mol Biol 2011; 45: 136-44.
13. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fi brosis. Lancet 2011; 378: 1949-61.
14. Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fi brosis. Ther Adv Respir Dis 2010; 4: 367-88.
15. Strieter RM, Mehrad B. New mechanisms of pulmonary fi brosis. Chest 2009; 136: 1364-70.
16. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classifi cation of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277-304.
17. Visscher DW, Myers JL. Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 322-29.
18. Misumi S, Lynch DA. Idiopathic pulmonary fi brosis/usual interstitial pneumonia: imaging diagnosis, spectrum of abnormalities, and temporal progression. Proc Am Thorac Soc 2006; 3: 307-14.
19. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fi brosis? Int J Biochem Cell Biol 2008; 40: 362-82.
20. Moore BB, Hogaboam CM. Murine models of pulmonary fi brosis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L152-60.
21. Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, Brown KK. Fibroblast foci are not discrete sites of lung injury or repair: the fi broblast reticulum. Am J Respir Crit Care Med 2006; 174: 654-58.
22. Enomoto N, Suda T, Kato M, et al. Quantitative analysis of fi broblastic foci in usual interstitial pneumonia. Chest 2006; 130: 22-29.
23. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003; 167: 1410-15.
24. Martin TR, Hagimoto N, Nakamura M, Matute-Bello G. Apoptosis and epithelial injury in the lungs. Proc Am Thorac Soc 2005; 2: 214-20.
25. Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fi brosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006; 103: 13180-05.
26. Gardner A, Fisher AJ, Richter C, et al. The critical role of TAK1 in accentuated epithelial to mesenchymal transition in obliterative bronchiolitis after lung transplantation. Am J Pathol 2012; 180: 2293-308.
27. Jayachandran A, Konigshoff M, Yu H, et al. SNAI transcription factors mediate epithelial-mesenchymal transition in lung fi brosis. Thorax 2009; 64: 1053-61.
28. Pozharskaya V, Torres-Gonzalez E, Rojas M, et al. Twist: a regulator of epithelial-mesenchymal transition in lung fi brosis. PLoS One 2009; 4: e7559.
29. Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fi brosis. Am J Pathol 2005; 166: 1321-32.
30. Tanjore H, Xu XC, Polosukhin VV, et al. Contribution of epithelial-derived fi broblasts to bleomycin-induced lung fi brosis. Am J Respir Crit Care Med 2009; 180: 657-65.
31. Chapman HA, Li X, Alexander JP, et al. Integrin ?6?4 identifi es an adult distal lung epithelial population with regenerative potential in mice. J Clin Invest 2011; 121: 2855-62.
32. Rock JR, Barkauskas CE, Cronce MJ, et al. Multiple stromal populations contribute to pulmonary fi brosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci USA 2011; 108: E1475-83.
33. Konigshoff M, Kramer M, Balsara N, et al. WNT1-inducible signaling protein-1 mediates pulmonary fi brosis in mice and is upregulated in humans with idiopathic pulmonary fi brosis. J Clin Invest 2009; 119: 772-87.
34. Milara J, Navarro R, Juan G, et al. Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fi brosis and mediates epithelial to mesenchymal transition. Thorax 2012; 67: 147-56.
35. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528-39.
36. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11: 1173-79.
37. Li Y, Jiang D, Liang J, et al. Severe lung fi brosis requires an invasive fi broblast phenotype regulated by hyaluronan and CD44. J Exp Med 2011; 208: 1459-71.
38. Venkatesan N, Ouzzine M, Kolb M, Netter P, Ludwig MS. Increased deposition of chondroitin/dermatan sulfate glycosaminoglycan and upregulation of ?1,3-glucuronosyltransferase I in pulmonary fi brosis. Am J Physiol Lung Cell Mol Physiol 2011; 300: L191-203.
39. Que J, Wilm B, Hasegawa H, Wang F, Bader D, Hogan BL. Mesothelium contributes to vascular smooth muscle and mesenchyme during lung development. Proc Natl Acad Sci USA 2008; 105: 16626-30.
40. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011; 21: 193-215.
41. Rajkumar VS, Shiwen X, Bostrom M, et al. Platelet-derived growth factor-? receptor activation is essential for fi broblast and pericyte recruitment during cutaneous wound healing. Am J Pathol 2006; 169: 2254-65.
42. Sundberg C, Ivarsson M, Gerdin B, Rubin K. Pericytes as collagen-producing cells in excessive dermal scarring. Lab Invest 1996; 74: 452-66.
43. Liu Y. Cellular and molecular mechanisms of renal fi brosis. Nat Rev Nephrol 2011; 7: 684-96.
44. Lin SL, Kisseleva T, Brenner DA, Duffi eld JS. Pericytes and perivascular fi broblasts are the primary source of collagen-producing cells in obstructive fi brosis of the kidney. Am J Pathol 2008; 173: 1617-27.
45. Humphreys BD, Lin SL, Kobayashi A, et al. Fate tracing reveals the pericyte and not epithelial origin of myofi broblasts in kidney fi brosis. Am J Pathol 2010; 176: 85-97.
46. Fabian SL, Penchev RR, St-Jacques B, et al. Hedgehog-Gli pathway activation during kidney fi brosis. Am J Pathol 2012; 180: 1441-53.
47. Goritz C, Dias DO, Tomilin N, Barbacid M, Shupliakov O, Frisen J. A pericyte origin of spinal cord scar tissue. Science 2011; 333: 238-42.
48. Liu Q, Zhang Y, Mao H, et al. A crosstalk between the Smad and JNK signaling in the TGF-beta-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells. PLoS One 2012; 7: e32009.
49. Patel P, West-Mays J, Kolb M, Rodrigues JC, Hoff CM, Margetts PJ. Platelet derived growth factor B and epithelial mesenchymal transition of peritoneal mesothelial cells. Matrix Biol 2010; 29: 97-106.
50. Nasreen N, Mohammed KA, Mubarak KK, et al. Pleural mesothelial cell transformation into myofi broblasts and haptotactic migration in response to TGF-?1 in vitro. Am J Physiol Lung Cell Mol Physiol 2009; 297: L115-24.
51. Mubarak KK, Montes-Worboys A, Regev D, et al. Parenchymal traffi cking of pleural mesothelial cells in idiopathic pulmonary fi brosis. Eur Respir J 2012; 39: 133-40.
52. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fi brosis: aberrant recapitulation of developmental programs? PLoS Med 2008; 5: e62.
53. Liu T, Dhanasekaran SM, Jin H, et al. FIZZ1 stimulation of myofi broblast diff erentiation. Am J Pathol 2004; 164: 1315-26.
54. Liu T, Hu B, Choi YY, et al. Notch1 signaling in FIZZ1 induction of myofi broblast diff erentiation. Am J Pathol 2009; 174: 1745-55.
55. Ding H, Zhou D, Hao S, et al. Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fi brosis. J Am Soc Nephrol 2012; 23: 801-13.
56. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003; 422: 313-17.
57. Fitch PM, Howie SE, Wallace WA. Oxidative damage and TGF-beta diff erentially induce lung epithelial cell sonic hedgehog and tenascin-C expression: implications for the regulation of lung remodelling in idiopathic interstitial lung disease. Int J Exp Pathol 2011; 92: 8-17.
58. Konigshoff M, Dumitrascu R, Udalov S, et al. Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fi brosis: a rationale for therapeutic intervention. Thorax 2010; 65: 949-55.
59. Fabre A, Marchal-Somme J, Marchand-Adam S, et al. Modulation of bleomycin-induced lung fi brosis by serotonin receptor antagonists in mice. Eur Respir J 2008; 32: 426-36.
60. Ebrahimkhani MR, Oakley F, Murphy LB, et al. Stimulating healthy tissue regeneration by targeting the 5-HT(2)B receptor in chronic liver disease. Nat Med 2011; 17: 1668-73.
61. Funke M, Zhao Z, Xu Y, Chun J, Tager AM. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol 2012; 46: 355-64.
62. Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fi brosis to lung injury by mediating fi broblast recruitment and vascular leak. Nat Med 2008; 14: 45-54.
63. Fang X, Yu S, LaPushin R, et al. Lysophosphatidic acid prevents apoptosis in fi broblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J 2000; 352: 135-43.
64. Bozyk PD, Moore BB. Prostaglandin E2 and the pathogenesis of pulmonary fi brosis. Am J Respir Cell Mol Biol 2011; 45: 445-52.
65. Maher TM, Evans IC, Bottoms SE, et al. Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2010; 182: 73-82.
66. Walker NM, Badri LN, Wadhwa A, Wettlaufer S, Peters-Golden M, Lama VN. Prostaglandin E2 as an inhibitory modulator of fi brogenesis in human lung allografts. Am J Respir Crit Care Med 2012; 185: 77-84.
67. Dackor RT, Cheng J, Voltz JW, et al. Prostaglandin E(2) protects murine lungs from bleomycin-induced pulmonary fi brosis and lung dysfunction. Am J Physiol Lung Cell Mol Physiol 2011; 301: L645-55.
68. Orphan drug status for LPA1 antagonist AM152 for treatment of idiopathic pulmonary fi brosis. Press release. http://www.science20. com/news-articles/ orphan-drug-status-lpa1-antagonist-am152-treatment-idiopathic-pulmonary- fibrosis-78315 (accessed April 22, 2011).
69. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891-906.
70. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010; 16: 1009-17.
71. Rodriguez HM, Vaysberg M, Mikels A, et al. Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor. J Biol Chem 2010; 285: 20964-74.
72. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003; 4: 140-56.
73. Olsen KC, Sapinoro RE, Kottmann RM, et al. Transglutaminase 2 and its role in pulmonary fi brosis. Am J Respir Crit Care Med 2011; 184: 699-707.
74. Huang X, Yang N, Fiore VF, et al. Matrix stiff ness-induced myofi broblast diff erentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol 2012; published online March 29. DOI:10.1165/rcmb.2012- 0050OC.
75. Hinz B. Tissue stiff ness, latent TGF-β1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fi brosis. Curr Rheumatol Rep 2009; 11: 120-26.
76. Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J. NOX4/NADPH oxidase expression is increased in pulmonary fi broblasts from patients with idiopathic pulmonary fi brosis and mediates TGFβ1-induced fi broblast diff erentiation into myofi broblasts. Thorax 2010; 65: 733-38.
77. Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofi broblast activation and fi brogenic responses to lung injury. Nat Med 2009; 15: 1077-81.
78. Bondi CD, Manickam N, Lee DY, et al. NAD(P)H oxidase mediates TGF-β1-induced activation of kidney myofi broblasts. J Am Soc Nephrol 2010; 21: 93-102.
79. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fi brosis. N Engl J Med 2012; 366: 1968-77.
80. Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. Nat Rev Cardiol 2009; 6: 419-29.
81. Lorenzen JM, Haller H, Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 2011; 7: 286-94.
82. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA. MicroRNAs and the regulation of fi brosis. FEBS J 2010; 277: 2015-21.
83. Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2010; 182: 220-29.
84. Yang S, Banerjee S, de Freitas A, et al. Participation of miR-200 in pulmonary fi brosis. Am J Pathol 2012; 180: 484-93.
85. Ryter SW, Nakahira K, Haspel JA, Choi AM. Autophagy in pulmonary diseases. Annu Rev Physiol 2012; 74: 377-401.
86. Haspel JA, Choi AM. Autophagy: a core cellular process with emerging links to pulmonary disease. Am J Respir Crit Care Med 2011; 184: 1237-46.
87. Chen ZH, Lam HC, Jin Y, et al. Autophagy protein microtubule-associated protein 1 light chain-3B (LC3B) activates extrinsic apoptosis during cigarette smoke-induced emphysema. Proc Natl Acad Sci USA 2010; 107: 18880-05.
88. Chen ZH, Kim HP, Sciurba FC, et al. Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. PLoS One 2008; 3: e3316.
89. Jin Y, Tanaka A, Choi AM, Ryter SW. Autophagic proteins: new facets of the oxygen paradox. Autophagy 2012; published online March 1. DOI:10.4161/auto.19258.
90. Yang HZ, Wang JP, Mi S, et al. TLR4 activity is required in the resolution of pulmonary infl ammation and fi brosis after acute and chronic lung injury. Am J Pathol 2012; 180: 275-92.
91. Patel A LL, Geyer A, Haspel JA, et al. Autophagy in idiopathic pulmonary fi brosis. PLoS One 2012; 7: e41394.
92. Konigshoff M, Schwarz J, Eickelberg O. Human lung stem cells: Oh, the places you'll go! EMBO Mol Med 2011; 3: 575-77.
93. Ghosh M, Helm KM, Smith RW, et al. A single cell functions as a tissue-specifi c stem cell and the in vitro niche-forming cell. Am J Respir Cell Mol Biol 2011; 45: 459-69.
94. Rock JR, Onaitis MW, Rawlins EL, et al. Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc Natl Acad Sci USA 2009; 106: 12771-75.
95. Zhang Y, Goss AM, Cohen ED, et al. A Gata6-Wnt pathway required for epithelial stem cell development and airway regeneration. Nat Genet 2008; 40: 862-70.
96. Rock JR, Gao X, Xue Y, Randell SH, Kong YY, Hogan BL. Notch-dependent diff erentiation of adult airway basal stem cells. Cell Stem Cell 2011; 8: 639-48.